Change in moles linked to use of unlicensed "sun tan jab"

BMJ (Online)

Volumn 338, Issue 7689, 2009, Pages 251-

  Langan, Ewan A ^a   Ramlogan, Denise ^b   Jamieson, Lynne A ^b   Rhodes, Lesley E ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERMEDIN DERIVATIVE; MELANOTAN II; MELATONAN I; UNCLASSIFIED DRUG;

ADULT; CASE REPORT; CLINICAL FEATURE; DRUG CONTAMINATION; DRUG SAFETY; DRUG UTILIZATION; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; INTERNET; LETTER; OFF LABEL DRUG USE; PIGMENTED NEVUS; PRIORITY JOURNAL; SKIN PIGMENTATION; SUN EXPOSURE;

ADULT; ALPHA-MSH; DERMATOLOGIC AGENTS; FEMALE; HUMANS; NEVUS, PIGMENTED; PEPTIDES, CYCLIC; SKIN NEOPLASMS; SUNTAN;

EID: 78650759802     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b277     Document Type: Letter

References (5)

1. Thirwell C, Nathan P. Melanoma - Part 2: management. BMJ 2008;337:a2488. (1 December.)
2. Dorr RT, Ertl G, Levine N, Brooks C, Bangert JL, Powell MB, et al. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Arch Dermatol 2004;140:827-35.
3. Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-1 clinical trial. Life Sci 1996;58:1777-84.
4. Barnetson RS, Ooi TK, Zhuang L, Halliday GM, Reid CM, Walker PC, et al. [Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J Invest Dermatol 2006;126:1869-78.
5. Medicines and Healthcare products Regulatory Agency (MHRA). Press release. "Tan-jab" is an unlicensed medicine and may not be safe - warns medicines regulator. www.mhra.gov.uk/NewsCentre/Pressreleases/CON031009 (accessed 25 Nov 2008.)